FDA-IND (INVESTIGATIONAL NEW DRUG) EXPANDED ACCESS "COMPASSIONATE USE" SUBMISSION 2022
BOTH FORMULAS CONTAIN INDIVIDUAL ORGANIC COMOUND ELEMENTS THAT HAVE BEEN EVALUATED AND LISTED AS SAFE AND EFFECTIVE FOR USE IN OTHER PATHOLOGICAL DISEASE DIAGNOSES INDICATIONS AND, BOTH FORMULAS CONTAIN ONLY COMPONENTS WHICH HAVE BEEN ISSUED INDIVIDUAL 2022 FDA-NDC NATIONAL DRUG CODES
FDA IS CURRENTLY IN OFFICIAL REVIEW FOR VALIDATION
RESTORITROL: IV NTR3 NEURO FOR PRODUCT NDC LABELING
Comments